Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

21 avr. 2026 06h39 HE | Source: Research and Markets

Immuno-Oncology Drugs Market Opportunity Analysis and Forecast Report 2026-2035: Merck & Co. Remains a Dominant Force, Supported by the Commercial Success of Keytruda

Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Drugs Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035" report has been added to ResearchAndMarkets.com's...
21 avr. 2026 04h13 HE | Source: Research and Markets

Trispecific Antibodies Market Landscape Report 2026: Opportunity and Proprietary Insights - 90 Trispecific Antibodies by Company, Country, Indication & Phase

Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Trispecific Antibodies Market Opportunity, Proprietary Technologies & Clinical Trials Insight 2026" report has been added to ...
03 févr. 2026 07h51 HE | Source: Research and Markets

Cancer Immunotherapy Research Report 2026: Market Forecasts 2025-2029 for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer with Executive and Consultant Guides

Dublin, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market 2025-2029 - Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer, with Executive and Consultant...
10 déc. 2025 09h15 HE | Source: Research and Markets

China Leads Therapeutic Access with 74 Approved Immuno-Oncology Agents

Dublin, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The "Strategic Intelligence: Immuno-oncology (2025)" has been added to ResearchAndMarkets.com's offering. The latest report delves into the dynamic...
02 déc. 2025 04h10 HE | Source: Research and Markets

Abemaciclib Research Report 2025: Eli Lilly and Company Dominates the $1.6 Billion Market - Long-term Forecasts to 2029 and 2034

Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Abemaciclib Market Report 2025" report has been added to ResearchAndMarkets.com's offering.The abemaciclib market size has grown rapidly in recent...
27 nov. 2025 08h58 HE | Source: Research and Markets

CD40 Agonists and CD40/L Antagonists Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of CD40 Agonists and CD40/L Antagonists" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
13 nov. 2025 08h25 HE | Source: Candel Therapeutics

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved...
22 sept. 2025 04h32 HE | Source: Research and Markets

Growth Opportunities in the Immuno-oncology Therapeutics Market, 2024-2030: Advances in Next-Gen Immunotherapies, AI, and Biomarker-Driven Personalization are Driving Transformational Growth

Dublin, Sept. 22, 2025 (GLOBE NEWSWIRE) -- The "Growth Opportunities in the Immuno-oncology Therapeutics Market, 2024-2030" report has been added to ResearchAndMarkets.com's offering. The revenue...
08 sept. 2025 10h39 HE | Source: Research and Markets

Trends & Strategies in the $54 Billion PD-1 & PD-L1 Inhibitors Market 2025: Industry Revenues Will More Than Double by 2030

Dublin, Sept. 08, 2025 (GLOBE NEWSWIRE) -- The "PD-1 & PD-L1 Inhibitors Market Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering. The PD-1 & PD-L1 Inhibitors...
02 sept. 2025 06h06 HE | Source: Research and Markets

Immuno-oncology Clinical Trials Markets and Competition Report 2025-2030: Analysis by Therapy Type, Trial Phase, Indication, Sponsor Type, Trial Type, Patient Enrollment and Region

Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The "Immuno-oncology Clinical Trials Market by Therapy Type (Adoptive Cell Therapies, Cancer Vaccines, Checkpoint Inhibitors), Trial Phase (Phase I, Phase...

Page suivante